Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2026-03-12

No results posted yet for this study

Summary

This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.

Conditions

  • Amyloidosis
  • Amyloid
  • Amyloid Neuropathies, Familial
  • Amyloid Cardiomyopathy
  • Amyloid - Primary
  • Transthyretin Amyloidosis
  • AL Amyloidosis

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Mazen A Hanna, MD · The Cleveland Clinic

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2026-03-09
Completion
2026-03-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431896 on ClinicalTrials.gov